FDA Pushes Lilly’s Oral GLP-1 Approval to April, Shares Slide 4%
FDA extended review of Lilly’s oral GLP-1 candidate orforglipron to April 10 from end-February, triggering a 4% share drop. Analysts argue Lilly’s Zepbound efficacy, growing weight-loss leadership and strong pipeline will offset any long-term revenue impact.
Related News
NVDA
Nvidia Tops $91B Sales Forecast, Boosts Dividend and Buyback Program
NVDA•
NVDA
Nvidia’s AI Chip Revenue Forecast Beats Estimates but Shares Drop 1.3%
NVDA•
DAO
Youdao Q1 Revenue Rises 3.8% to RMB1.3B, Marketing Jumps 20.9%
DAO•
C
SpaceX Reveals $1.45B Bitcoin Stake Ahead of $1.75T IPO
C•
WMT
Walmart Set for Q1 EPS of $0.66 on $175B Revenue; Value Outlook Tempered
WMT•
Sources
FFDD